F2G to use $70m financing to advance olorofilm
British antifungal developer F2G Ltd has announced a $70mn financing round to push development of its late-stage compound olorofilm.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
Sosei announces $1.2bn R&D collaboration with Abbvie
/in News/by Thomas GabrielczykSosei Heptares and AbbVie have inked a multi-target licence option drug discovery agreement in neurology.
UK-Spanish team to optimise efficacy of microbial production processes
/in News/by Thomas GabrielczykResearchers have presented a novel method to promote biofilm formation and thus to increase efficiency of biocatalysis in biotech production.
InflaRX set to file for MAA for vilobelimab
/in News/by Thomas GabrielczykInflaRx plans to apply for Emergency Use Authorization from the US FDA in Q3/2022 for vilobelimab, the company’s treatment for critically ill COVID-19 patients.
New antibody cocktail might fight all corona variants
/in News/by Thomas GabrielczykA nasal antibody cocktail binding to the conserved S2 stalk region of SARS-COV-2 might end the corona pandemic.
Ring exchange at Roche’s top executive level
/in News/by Thomas GabrielczykSchwan follows Franz, Schinecker follows Schwan.
French-German Novasep-PharmaZell Group invests EUR7.3M at Mourenx site
/in News/by Thomas GabrielczykThis new investment will support the growth of the Mourenx site and sustain the growing demand for production of active pharmaceutical ingredients (APIs), particularly the highly potent drugs (HPAPIs) used […]
Oxford Science Enterprises raised a further £250 million ($300 million) in funding
/in News/by Thomas GabrielczykOxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, announced it has raised a […]
Swedish Bioinvent issues shares worth SEK299m (USD28m)
/in News/by Thomas GabrielczykBioInvent has successfully carried out a directed share issue of approximately SEK 300 million (approximately USD 28.3 million). A number of international and Swedish investors participated, including new investors such […]
Immunocore has a sip with USD140m private placement
/in News/by Thomas GabrielczykImmunocore sells around 3.7m shares in a private placement with a 20% discount and gets USD140m to advance its pipline.